149 related articles for article (PubMed ID: 28301567)
1. Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients.
Heng J; Guo X; Wu W; Wang Y; Li G; Chen M; Peng L; Wang S; Dai L; Tang L; Wang J
PLoS One; 2017; 12(3):e0174022. PubMed ID: 28301567
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
[TBL] [Abstract][Full Text] [Related]
3. Integrated analysis of promoter methylation and expression of telomere related genes in breast cancer.
Heng J; Zhang F; Guo X; Tang L; Peng L; Luo X; Xu X; Wang S; Dai L; Wang J
Oncotarget; 2017 Apr; 8(15):25442-25454. PubMed ID: 28424414
[TBL] [Abstract][Full Text] [Related]
4. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
5. The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection.
Zeng F; Heng J; Guo X; Wang Y; Wu W; Tang L; Chen M; Wang S; Deng H; Wang J
Breast Cancer Res Treat; 2020 Feb; 180(1):237-245. PubMed ID: 31983017
[TBL] [Abstract][Full Text] [Related]
6. Alteration in methylation pattern of oncogene Akt1 promoter region in bladder cancer.
Sun XF; Sun ZY; Pan B; Li L; Shen W
Mol Biol Rep; 2012 May; 39(5):5631-6. PubMed ID: 22189542
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
Deng L; Zhu X; Sun Y; Wang J; Zhong X; Li J; Hu M; Zheng H
Cancer Res Treat; 2019 Jan; 51(1):128-140. PubMed ID: 29540052
[TBL] [Abstract][Full Text] [Related]
8. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.
Barekati Z; Radpour R; Kohler C; Zhang B; Toniolo P; Lenner P; Lv Q; Zheng H; Zhong XY
Hum Mol Genet; 2010 Aug; 19(15):2936-46. PubMed ID: 20466735
[TBL] [Abstract][Full Text] [Related]
9. Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients.
Li Z; Guo X; Wu Y; Li S; Yan J; Peng L; Xiao Z; Wang S; Deng Z; Dai L; Yi W; Xia K; Tang L; Wang J
Breast Cancer Res Treat; 2015 Feb; 149(3):767-79. PubMed ID: 25636590
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
11. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA
Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821
[TBL] [Abstract][Full Text] [Related]
12. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients.
Real SAS; Parveen F; Rehman AU; Khan MA; Deo SVS; Shukla NK; Husain SA
BMC Cancer; 2018 Jul; 18(1):711. PubMed ID: 29970036
[TBL] [Abstract][Full Text] [Related]
14. Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.
Shimoi T; Hashimoto J; Sudo K; Shimomura A; Noguchi E; Shimizu C; Yunokawa M; Yonemori K; Yoshida H; Yoshida M; Kato T; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
BMC Cancer; 2021 Oct; 21(1):1131. PubMed ID: 34670536
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
[TBL] [Abstract][Full Text] [Related]
16. HOXD13 methylation status is a prognostic indicator in breast cancer.
Zhong Z; Shan M; Wang J; Liu T; Xia B; Niu M; Ren Y; Pang D
Int J Clin Exp Pathol; 2015; 8(9):10716-24. PubMed ID: 26617782
[TBL] [Abstract][Full Text] [Related]
17. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
[TBL] [Abstract][Full Text] [Related]
18. Novel transcripts from a distinct promoter that encode the full-length AKT1 in human breast cancer cells.
Schmidt JW; Wehde BL; Sakamoto K; Triplett AA; West WW; Wagner KU
BMC Cancer; 2014 Mar; 14():195. PubMed ID: 24628780
[TBL] [Abstract][Full Text] [Related]
19. PTEN promoter is methylated in a proportion of invasive breast cancers.
Khan S; Kumagai T; Vora J; Bose N; Sehgal I; Koeffler PH; Bose S
Int J Cancer; 2004 Nov; 112(3):407-10. PubMed ID: 15382065
[TBL] [Abstract][Full Text] [Related]
20. Lowly methylated region analysis identifies EBF1 as a potential epigenetic modifier in breast cancer.
Fernandez-Jimenez N; Sklias A; Ecsedi S; Cahais V; Degli-Esposti D; Jay A; Ancey PB; Woo HD; Hernandez-Vargas H; Herceg Z
Epigenetics; 2017; 12(11):964-972. PubMed ID: 29099283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
